Clinical Trials
6
Active:1
Completed:3
Trial Phases
2 Phases
Phase 1:1
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (80.0%)Phase 1
1 (20.0%)Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy
Phase 2
Terminated
- Conditions
- Prostate Cancer
- Interventions
- Drug: Treatment with WST09 Vascular Photodynamic therapy
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- STEBA France
- Target Recruit Count
- 16
- Registration Number
- NCT00312442
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy
Phase 2
Completed
- Conditions
- Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure
- Interventions
- Drug: WST09
- First Posted Date
- 2006-03-30
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- STEBA France
- Target Recruit Count
- 28
- Registration Number
- NCT00308919
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: Treatment with Tookad VTP
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- STEBA France
- Target Recruit Count
- 8
- Registration Number
- NCT00305929
- Locations
- 🇨🇦
The Prostate Centre Princess Margaret Hospital, Toronto, Ontario, Canada
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
Phase 1
Completed
- Conditions
- EsophagitisGastroesophageal RefluxStomach UlcerDuodenal Ulcer
- Interventions
- Drug: S-Tenatoprazole-Na (STU-Na)
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- STEBA France
- Target Recruit Count
- 32
- Registration Number
- NCT00284908
- Locations
- 🇺🇸
Healthcare Discoveries, Inc., San Antonio, Texas, United States
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
Phase 2
Suspended
- Conditions
- Esophagitis, Reflux
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2008-03-19
- Lead Sponsor
- STEBA France
- Target Recruit Count
- 450
- Registration Number
- NCT00282555
News
No news found